Assessing the Benefit of Specialist Palliative Care in Oncology: Rethinking Clinical Trial Design

David Hui^{1

2}, Mellar P Davis³, Jennifer S Temel⁴, Dustin J Rabideau^{5

6}, Camilla Zimmermann^{7

8}

Affiliations

¹ Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
³ Department of Supportive Oncology, Levine Cancer Institute, Charlotte, NC.
⁴ Department of Medicine, Massachusetts General Hospital, Boston, MA.
⁵ Department of Biostatistics, Massachusetts General Hospital, Boston, MA.
⁶ Department of Medicine, Harvard Medical School, Boston, MA.
⁷ Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
⁸ Division of Palliative Medicine and Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, ON, Canada.

David Hui et al. J Clin Oncol. 2026.

. 2026 Feb 10;44(5):349-355.

doi: 10.1200/JCO-25-02206. Epub 2025 Dec 16.

David Hui^{1

2}, Mellar P Davis³, Jennifer S Temel⁴, Dustin J Rabideau^{5

6}, Camilla Zimmermann^{7

8}

¹ Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
³ Department of Supportive Oncology, Levine Cancer Institute, Charlotte, NC.
⁴ Department of Medicine, Massachusetts General Hospital, Boston, MA.
⁵ Department of Biostatistics, Massachusetts General Hospital, Boston, MA.
⁶ Department of Medicine, Harvard Medical School, Boston, MA.
⁷ Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
⁸ Division of Palliative Medicine and Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, ON, Canada.

No abstract available

LinkOut - more resources